top of page
QProtyn Centre Panel Website.tif

Is your mAb optimized for
SubQ yet?

Cutting edge, viscosity-reduction technology for
monoclonal antibodies

Our patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance. 


HILOPRO   Technology


Upgrade your mAb from IV to SubQ.


Re-imagine your biologic API delivered subcutaneously in a single dose up to 450mg in a 1.5mL syringe.

Proof of concept for your mAb in
8 Weeks !

Active Senior Man

Contact Us

Thank you! We will get back to you shortly.

Qprotyn Contact
bottom of page